_version_ 1785019133242376192
author Jallouk, Andrew P.
Gouni, Sushanth
Westin, Jason
Feng, Lei
Mistry, Haleigh
Steiner, Raphael E.
James, Jinsu
Noorani, Mansoor
Horowitz, Sandra
Puebla-Osorio, Nahum
Fayad, Luis E.
Iyer, Swaminathan P.
Hawkins, Misha
Flowers, Christopher R.
Ahmed, Sairah
Nastoupil, Lo retta J
Kebriaei, Partow
Shpall, Elizabeth J.
Neelapu, Sattva S.
Nieto, Yago
Strati, Paolo
author_facet Jallouk, Andrew P.
Gouni, Sushanth
Westin, Jason
Feng, Lei
Mistry, Haleigh
Steiner, Raphael E.
James, Jinsu
Noorani, Mansoor
Horowitz, Sandra
Puebla-Osorio, Nahum
Fayad, Luis E.
Iyer, Swaminathan P.
Hawkins, Misha
Flowers, Christopher R.
Ahmed, Sairah
Nastoupil, Lo retta J
Kebriaei, Partow
Shpall, Elizabeth J.
Neelapu, Sattva S.
Nieto, Yago
Strati, Paolo
author_sort Jallouk, Andrew P.
collection PubMed
description
format Online
Article
Text
id pubmed-10071112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-100711122023-04-05 Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response Jallouk, Andrew P. Gouni, Sushanth Westin, Jason Feng, Lei Mistry, Haleigh Steiner, Raphael E. James, Jinsu Noorani, Mansoor Horowitz, Sandra Puebla-Osorio, Nahum Fayad, Luis E. Iyer, Swaminathan P. Hawkins, Misha Flowers, Christopher R. Ahmed, Sairah Nastoupil, Lo retta J Kebriaei, Partow Shpall, Elizabeth J. Neelapu, Sattva S. Nieto, Yago Strati, Paolo Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-11-17 /pmc/articles/PMC10071112/ /pubmed/36384251 http://dx.doi.org/10.3324/haematol.2022.281954 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Letter to the Editor
Jallouk, Andrew P.
Gouni, Sushanth
Westin, Jason
Feng, Lei
Mistry, Haleigh
Steiner, Raphael E.
James, Jinsu
Noorani, Mansoor
Horowitz, Sandra
Puebla-Osorio, Nahum
Fayad, Luis E.
Iyer, Swaminathan P.
Hawkins, Misha
Flowers, Christopher R.
Ahmed, Sairah
Nastoupil, Lo retta J
Kebriaei, Partow
Shpall, Elizabeth J.
Neelapu, Sattva S.
Nieto, Yago
Strati, Paolo
Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
title Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
title_full Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
title_fullStr Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
title_full_unstemmed Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
title_short Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
title_sort axicabtagene ciloleucel in relapsed or refractory large b-cell lymphoma patients in complete metabolic response
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071112/
https://www.ncbi.nlm.nih.gov/pubmed/36384251
http://dx.doi.org/10.3324/haematol.2022.281954
work_keys_str_mv AT jalloukandrewp axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT gounisushanth axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT westinjason axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT fenglei axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT mistryhaleigh axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT steinerraphaele axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT jamesjinsu axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT nooranimansoor axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT horowitzsandra axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT pueblaosorionahum axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT fayadluise axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT iyerswaminathanp axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT hawkinsmisha axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT flowerschristopherr axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT ahmedsairah axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT nastoupillorettaj axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT kebriaeipartow axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT shpallelizabethj axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT neelapusattvas axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT nietoyago axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse
AT stratipaolo axicabtageneciloleucelinrelapsedorrefractorylargebcelllymphomapatientsincompletemetabolicresponse